Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide pilot trial in moderate-to-severe Graves orbitopathy
NL-OMON38562Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of pasireotide LAR in Graves' ophthalmopathy (TED), sponsored by Amsterdam University Medical Center. Primary endpoint: Predefined combined clinical endpoints. Planned start Jul 2013; status: withdrawn.
02
Drugs
pasireotide LAR
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NL-OMON38562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38562.